News

TSO3 DISCLOSES FOURTH QUARTER AND FULL YEAR 2012 FISCAL RESULTS

Quebec City, March 20, 2013 – TSO3 Inc. (“TSO3”) an innovator in sterilization technology for medical devices in healthcare settings, today reported sales for the fiscal year ending December 31, 2012 totalling $1,162,922 compared to $3,145,162 in 2011. Most of the sales in 2012, or $1,037,545, were made during the first semester while, in 2011, most of the sales or $2,357,745 were made in the second semester. The end of shipments under the upgrade program and a decrease in orders placed by the 3M Company created a sharp contraction in sales in Q2-2012. Sales to the 3M Company during the first semester of 2012 were 69% lower than in the last semester of 2011.

Read more

News

TSO3: conference call and webcast for the 2012 annual financial results

Quebec City, Quebec, Canada, March 7, 2013 – TSO3 Inc. (“TSO3”) (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it will report the Company’s annual financial results ending December 31, 2012, on Wednesday, March 20, 2013. TSO3 will host a conference call at 10:30 A.M. (EDT) the same day.

Read more

News

TSO3 CLOSES $7,000,000 BOUGHT DEAL

Québec City, March 4, 2013 – TSO3 Inc. (“TSO3” or the “Company”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, is pleased to announce today that it has successfully completed its previously announced public offering of 7,000,000 common shares (the “Common Shares”). The offering was completed on a bought deal basis through a syndicate of underwriters co-led by Desjardins Securities Inc. and Canaccord Genuity Corp. and including Byron Capital Markets Ltd. and Laurentian Bank Securities Inc., at a price of $1.00 per Common Share for aggregate gross proceeds to TSO3 of $7,000,000 (the “Offering”).

Read more